de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross W L
Department of Rheumatology, Medical University of Lübeck, Rheumaklinik Bad Bramstedt GmbH, Germany.
J Rheumatol. 1998 Mar;25(3):492-5.
To study the efficacy of methotrexate (MTX) plus low dose corticosteroids for induction of remission in generalized Wegener's granulomatosis (WG) and to possibly identify predictive factors for the outcome under this therapy.
We conducted a prospective, open label study, including 17 patients with not immediately life threatening, generalized WG. Treatment consisted of intravenous MTX 0.3 mg/kg once weekly plus daily oral low dose prednisone for initial diagnosis of WG in 11 and for a generalized relapse of WG in 6 patients. Interdisciplinary, standardized assessments of disease activity and extent were done 3-monthly.
Within a median treatment period of 24.5 months remission could be achieved in 10/17 patients (59%), their median corticosteroid dose during that time was 1.75 mg/day. Seven patients with a median concomitant prednisone dose of 7.5 mg/day did not respond, among them 4 patients who were treated for a relapse of WG. Signs of de novo glomerulonephritis occurred in 5 of the 7 nonresponders. Significant side effects, including opportunistic infections, did not occur.
Weekly low dose MTX in combination with low dose corticosteroids leads to an acceptable remission rate of almost 60% without significant side effects. Patients treated for a relapse of WG and patients with a need for a higher concomitant prednisone dose seem to be at risk for nonresponse, with a high likelihood of developing de novo glomerulonephritis.
研究甲氨蝶呤(MTX)联合低剂量皮质类固醇诱导全身性韦格纳肉芽肿(WG)缓解的疗效,并确定该治疗方案疗效的预测因素。
我们进行了一项前瞻性、开放标签研究,纳入17例无即刻生命危险的全身性WG患者。治疗方案为静脉注射MTX 0.3 mg/kg,每周1次,加每日口服低剂量泼尼松,其中11例用于WG初诊,6例用于WG全身性复发。每3个月进行跨学科、标准化的疾病活动度和范围评估。
在中位治疗期24.5个月内,10/17例患者(59%)实现缓解,在此期间他们的中位皮质类固醇剂量为1.75 mg/天。7例患者中位泼尼松伴随剂量为7.5 mg/天,治疗无效,其中4例为WG复发患者。7例无效患者中有5例出现新发肾小球肾炎迹象。未发生包括机会性感染在内的严重副作用。
每周低剂量MTX联合低剂量皮质类固醇可使缓解率达到近60%,且无明显副作用。因WG复发接受治疗的患者以及需要更高剂量泼尼松伴随治疗的患者似乎有治疗无效的风险,且新发肾小球肾炎的可能性很高。